Goldman Sachs
VYNT

Goldman Sachs’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Goldman Sachs’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-77
Closed -$23K – 7245
2016
Q2 		$23K Buy
+77
New +$27.1K ﹤0.01% 6676
2014
Q4 		– Sell
-82
Closed -$111K – 7368
2014
Q3 		$111K Sell
82
-2
-2% -$2.87K ﹤0.01% 6532
2014
Q2 		$143K Buy
84
+1
+1% +$1.9K ﹤0.01% 6404
2014
Q1 		$188K Sell
83
-29
-26% -$74.2K ﹤0.01% 6121
2013
Q4 		$231K Buy
+112
New +$242K ﹤0.01% 5869

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $3.02B AUM 34.37% 1-Year Est. Return

Goldman Sachs's VYNT Position: Q3 2016 in Review

Goldman Sachs sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2016, closing a stake of 77 shares — an estimated $23K sold.

Goldman Sachs first reported a position in VYNT in Q4 2013 and held it in 5 quarters. The position peaked at $231K in Q4 2013. 30 funds tracked by Wall St. Rank hold VYNT as of Q3 2016.

  • Goldman Sachs reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Goldman Sachs sold 77 Vyant Bio, Inc. Common Stock shares in Q3 2016, an estimated $23K.
  • Goldman Sachs first reported a position in Vyant Bio, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
  • Goldman Sachs's Vyant Bio, Inc. Common Stock position peaked at $231K in Q4 2013.
  • 30 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2016.

Based on Goldman Sachs's 13F filing for Q3 2016, filed 14 Nov 2016.